Proteins and peptides are ubiquitous in every cell and thus are vital for various biological functions. In recent years, there is an extensive growth in the development of various biologicals and large molecules like proteins and peptides. Now, they are replacing the market of existing organic based pharmaceuticals. This review article intends to summarize various structural modifications that are carried out in order to alter basic properties of peptides and proteins so that their solubility, absorption, permeability and various other problems associated with their delivery can be resolved. Thus they can offer significant therapeutic potential.
INTRODUCTION
The progress in peptides and proteins have given a boost to drug innovation and discovery, and challenge the skill of pharmaceutical developers to develop novel techniques and delivery methods for present and future therapies. Thus, the potential of proteins and peptides should not be surprising. The range of chemical diversity offered by this industry is not being possessed by any other class of biological molecules. They are like nature's tool box. The more we can use such natural proteins and peptides or their closely associated analogs, the higher will be its specificity and safety. The benefit of such structurally developed proteins and peptides derived from their physiologically active parent molecules over other molecules is that they substantially reduce the risk of unsought side effects.
Market Value
Owing to complexity and instability associated with protein and peptide drugs, they are mostly delivered by parenteral route. But with progressive development in industry, scientist have been able to develop other routes of delivery such as transdermal, inhalational, intranasal and oral but the preferred one is the oral route. The emergence of more advanced technologies will help in achieving the desired outcomes. The global market for protein drugs increased from $86.8 billion in 2007 to $95.2 billion in 2008 and was estimated to be $160.1 billion in 2013, a compound annual growth rate (CAGR) of 10.9%. 1 However, BCC Research projects the market to grow to nearly $179.1 billion by 2018 with a five-year CAGR of 5.6% from 2013 to 2018. 2 Several emerging proteins and peptides are in preclinical stage. In addition, there are fewer molecules which are already in final stage of clinical development and would be available commercially within the next few years. While a large number of peptides are undergoing clinical trials. Peptides can be used as the active ingredients of new drugs as well as "addones" to other pharmaceutical agents at their target sites to modify their biological action.
Drawbacks associated with proteins and peptides
As such, proteins and peptides are chemically and enzymatically instable. Enzymatic degradation affects both the fraction absorbed and also the half lives of peptides in the body. 7 The cleavage of peptide bond occurs either at the amino or carboxyl terminus of the chain by exopeptidases (i.e. aminopeptidase and carboxypeptidase). Proteins tend to aggregate themselves and interact with various components in biological environment which affect their biological activity, absorption and biodistribution. They are highly soluble with log P < 0 and unstable in acid environment of gastrointestinal tract. 6 They have poor absorption through biological membranes. Proteins and peptides are charged molecules that cannot penetrate through the lipophilic plasma membrane by transcellular transport. Also, they have a molecular size >500 Da which restricts its paracellular transport through the tight junctions. 7 Hence, their delivery through oral route becomes difficult. The contact time with the absorbing surface for the delivery system of proteins and peptides are too short to allow therapeutic level to be maintained for a long period of time. This results in incomplete absorption and failure to maintain sustained action with rapid plasma clearance and peculiar dose response curves. 5 They are prematurely uptake by tissues like reticuloendothelial system. Due to their unique physical and chemical properties, they pose both physical and chemical issues and thus their isolation, purification, formulation, and delivery of proteins represent significant challenges to pharmaceutical scientists. Thus, modifying such proteins and peptides not only solves various problems associated with them but surely increases therapies and cures for various diseases and ailments.
COMMERCIALLY AVAILABLE PROTEINS AND PEPTIDES
Commercially marketed proteins and peptides and their mode of action are summarized in Table 1 . 
STRUCTURAL MODIFICATION
For viable delivery of proteins and peptides via oral route, the physicochemical properties like (molecular weight, pH stability, hydrophobicity, molecular size, and ionization constant) and biological barriers (proteolysis in stomach, variable pH, poor permeation and membrane efflux) must be considered. This can be done by: (i) Modification of the physicochemical property like lipophilicity and enzyme susceptibility of the macromolecules; (ii) the addition of novel functionalism (e.g. receptor recognition or cell permeability) to macromolecules; or (iii) the use of a delivery carrier system. 6 The combination of these approaches might lead to a successful result.
The modification of the primary structure of a peptide leads to improvement on enzymatic stability and mucosal penetration. The bonding involved in such modifications can be covalent and non-covalent. Cova-lent modifications involve the chemical derivatization of the available functional groups of amino acids, peptides and proteins. Non-covalent modifications, on the other hand, involve the process by which the polymer chain acquires its proper three-dimensional structure. To modify proteins and peptides structurally not only improves delivery of such drugs but it would also increase patient compliance. Also the structural changes of such drugs are economically viable as compared to developing newer carrier systems. The different ways of structural modification of proteins and peptides are shown are shown in Figure 1 . The importance of such structural modification are:
solubility, stability, crystallinity, targetability and taste of drug are altered.
• The hydrolytic and enzymatic stability is enhanced.
• The permeability across intestinal epithelia will improve.
• Plasma half life of protein will increase.
• Residence time in the body is prolonged.
• Protein immunogenicity is reduced or eliminated.
• Adverse reactions are few.
• Shelf life is prolonged with increase in systemic circulation and systemic exposure of drug.
• Renal clearance is lowered.
• Patient-compliance is improved.
TECHNIQUES FOR STRUCTURAL MODIFICATION PRODRUG CONCEPT
Prodrugs are pharmacologically inactive entities which are made active by structural chemical modifications.
Prodrug strategies consist of a transient or reversible modification of the physicochemical properties of a given compound through chemical derivatization.
are some of the parameters which can be altered by prodrug. Thus, a prodrug increases chemical stability, alters aqueous solubility, improves bioavailability and provides hydrolytic stability to the drug. Prodrug maintains intrinsic pharmacological properties of the parent drug. Once the biological barrier is crossed, enzymatic or non-enzymatic reactions convert it into the parent drug ( Figure 2 ).
Cyclization
"Chemical linkers" are used for cyclization. They stabilize oligopeptides and improve their lipophilicity by reducing their charges and hydrogen bonding potential. The linkers were designed to be susceptible to esterase metabolism leading to release of the peptides. The cyclic prodrug was predicted to be possible for peptides with up to 8 to 9 amino acids. Many cyclic peptides and some of the newer experimental HIV protease and renin inhibitors have high inherent lipophilicity and thus poor aqueous solubility at physiological pH. The formulation of these compounds as aqueous parenteral dosage forms is difficult due to erratic oral bioavailability in animal models. Balkoves et al. introduced an ionisable moiety by synthesizing a water soluble phosphate monoester derivative of a lipopeptide by phosphorylation of the phenolic hydroxyl group of a homotyrosine residue. 10 The prodrug exhibited excellent hydrolytic stability and had comparable in vivo activity compared to the parent cyclic peptide, indicating that the prodrug undergoes enzymatic hydrolysis to generate the parent drug. The prodrug now possesses improved aqueous solubility with more sustained concentration in plasma. Borchard tet al. prepared acyloxyalkoxy-, phenyl propionic acid-and coumarinic acid-based cyclic prodrugs of [Leu ]-enkephalin (H-Tyr-Gly-Gly-Phe-Leu-OH) and its metabolically stable analog DADLE (H-Tyr-D-Ala-Gly-Phe-D-Leu-OH) and determined their biopharmaceutical and metabolic properties. 11 The cyclic prodrugs of these opioid peptides were shown to have:
(i) Unique solution structures that reduce their hydrogen bonding potential; (ii) Favourable physicochemical properties (e.g., increased lipophilicity) for membrane permeation; (iii) Metabolic stability to exo-and endopeptidase.
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Phosphorylation
Chong et al. prepared the phosphate monoester prodrugs of a series of a threonine and serine containing peptidomimetic HIV protease inhibitors. The introduction of an ionizable phosphate moiety significantly improved the aqueous solubility of these peptidomimetics. 12 William et al. and Kearney et al. found that these prodrugs showed the potent antiviral activity in a cell culture assay similar to corresponding parent molecules. Both serine and threonine linked phosphate prodrugs after intravenous administration in rats, showed slow rates of metabolic dephosphorylation. 13, 14 This can be due to the steric environment surrounding the phosphate group.
N, O-acyl migration reaction
Oliyai et al. and Bundgaard et al. used N,O-acyl migration reaction to enhance the aqueous solubility of polypeptides. O-peptide prodrug is formed when β-hydroxyl containing peptides can undergo acid-catalyzed N,O-acyl transfer. A protonated amine group is formed when rearrangement to the O-peptide takes place which impart more desirable solubility properties to the molecule.
15-18
N-alkylation
An alternative approach to increase the aqueous solubility of a polypeptide is N-alkylation of the peptide bond. Proline replaces alanine or leucine residue which has been shown to substantially improve the water solubility of a cyclic pentapeptide. The solubility enhancement has been attributed to the diminished structural regularity and lowering the intramolecular hydrogen bonding capability of the polypeptide.
19-21
Thiolation
A feasible site for prodrug modification is the thiol function of a polypeptide. Thioesterification, phosphorylation or disulfide formation are used for formation of thiol prodrugs of conventional xenobiotics and peptide mimetic compounds. Fournie et al. showed that the pharmacological effect of the drug entity is restored once the prodrugs are biologically converted to parent thiol. 
22-24
MODIFICATION IN N-OR C-TERMINUS OF THE PEPTIDE CHAINS
By conjugation with polymers PEGylation
PEGylation is considered as a gold standard for chemical modifications of protein drugs. It involves one or more polyethylene glycol (PEG) chains linked to a protein, peptide or non-peptide molecule (Fig. 3) . PEGylation is the term given to conjugation with monomethoxy poly (ethyleneglycol) or mPEG. PEG polymer, a polyether compound, or a polymer of ethylene oxide is highly soluble in water and is FDA approved. (Table 2) It improves the pharmacokinetics of drugs and increases the plasma half life of protein. This may be due to PEGylated protein is too large for glomerular filtration. It thus, sterically hinders the protein's interaction with cellular receptors required for metabolism and elimination. eg. PEGylated adenosine deaminase (PED-ADA) which is the first PEGylated approved product and used for ADA-deficiency. It is non-antigenic, nonimmunogenic and non-toxic. The PEG-drug conjugates have prolonged residence time, decreased degradation by metabolic enzymes, reduction or elimination of protein immunogenicity and increased protein stability. It also decreases protein aggregation, few adverse reactions, long shelf life. Thus increasing the systemic circulation and systemic exposure. It also improves patient-compliance. 27, 28 PEGylation enhances the potential of peptides and proteins as therapeutic agents and plays an important role in drug delivery. For maximum pharmacological benefits, a stable bond is formed between PEG and polypeptide. 28 To prepare an active PEG derivative with a functional group-such as active ester, active carbonate, tresylate or aldehyde suitable for coupling to a given target molecule a variety of chemical modifications are used. The polypeptide drug is then covalently linked by PEG derivative. Preferred positions for PEGylation are the N-terminal amino group of the polypeptide backbone and the ε-amino group in the side chain of the amino acid residue lysine. Being highly labile, mild chemical reaction conditions are used by proteins and peptides for the conjugation at the hydrophobic sites. 27, 28 Cazaliset al. prepared a strategy for site-specific PEGylation of a thrombomodulin (TM) derivative at the C-terminus. A shortened TM mutant which consists of epidermal growth factor (EGF)-like domains 4-6 was expressed in Escherichia coli with a C-terminal azido-methionine. The TM mutant was site-specifically conjugated to a methyl-PEG-triarylphosphine compound via the Staudinger reaction. Enzymatic activity of the TM so formed before and after PEGylation remain unchanged, confirming the efficacy of this sitespecific PEGylation scheme. 29 PEGylation improves the properties of several classes of protein drugs, such as enzymes, cytokines and antibodies. In general, the improvements are reduction of immunogenicity, increased retention time in the body and increased stability towards metabolic enzymes. The drawback associated with the PEGylation of proteins involves loss of biological activity and especially with PEGylation at N-terminus. But this is compensated by the increased stability, higher hydrodynamic volume and the prolonged body-residence time. An exemplary example is the PEGylated α-interferon Pegasys®, in which though only 7% of the antiviral activity of the native protein is retained, but because of the improved pharmacokinetics it shows a greatly improved performance in vivo compared with the unmodified enzyme. PEGylation, thus, helps in paracellular transport of proteins and peptides. 36 
Drawbacks of PEGylation
Some drawbacks associated with PEGylation are: Loss of pharmacological activity and loss of binding affinity with the drug target. PEG is non-biodegradable and thus, there is some evidence of enzyme driven low rate oxidation generating aldehydes and ketones. But it is not a normal detoxification mechanism. PEG end up in the tissues participating in the uptake of the PEGylated constructs where it will accumulate intralysomally when it is conjugated to therapeutic proteins which are large enough to escape kidney clearance. Additionally, PEGylated proteins generate anti-PEG antibodies that could influence the residence time of the conjugate in the circulating blood. Though, no adverse effects of PEG immunogenicity have been observed, possibly because of the very small amounts of injected PEGylated drugs currently in use. 34 Some pegylated drugs are mentioned in table 3. Poly(styrene-co-maleic acid anhydride) or SMA: It is a synthetic polymer, made up of styrene and maleic anhydride polymer, with molecular weight of 1.5 kDa, which on conjugation with proteins and peptide increases systemic circulation time and elimination half life of the conjugated drug to natural long-circulating blood plasma components such as serum albumin or lipoproteins. 27 Polysialation: It involves the conjugation of peptides and proteins to the naturally occurring, biodegradable α-(2→8) linked polysialic acid 3 . Polysialation is illustrated in Figure 4 . Polysialic acid is highly hydrophilic in nature which increases the systemic circulation. It has the advantage of being biodegradable and its catabolic products are not toxic (e.g. NeuNAc). It markedly reduces proteolysis, prolongs the half life in systemic circulation (up to 40 h) and retains the activity of protein and peptide in-vivo.It also reduces immunogenicity and antigenicity. Polysialic acids are linear polymers of N-acetylneuraminic acid (sialic acid) abundantly present on the surface of cells and many proteins. 3 Polysialylation has been tested and are used in therapeutics for the treatment of various diseases. It includes preservation of stability and function, optimal pharmacokinetics and pharmacodynamics, and reduced immunogenicity or antigenicity. 3 Gregoriadis et al. coupled covalently a low molecular weight polysialic acid, colominic acid with Erwinia carotovora L-asparginase (enzyme for treating leukemia) thus prolonging the circulation of the protein. The activity of the enzyme is retained and it is protected from inactivation in the presence of blood plasma with increase residence time in the circulation. 34 Jain et al. reacted the amino group of recombinant human insulin with the oxidized form of polysialic acids (colominic acid, 22 and 39 kDa) forming an aldehydic group. Polysialylationthus enhanced the therapeutic value of insulin with improved pharmacological properties with long term control of blood glucose level.
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Post Translational Modification
It is a step of protein synthesis which involves covalent addition of functional groups or polypeptide sequences to increase the functional diversity of the proteome. 37 The post translational modifications in proteins are of great importance for protein folding and function, especially in higher organisms. Besides shortening of the nascent polypeptide chain at the N-or C-terminus, phosphorylation and glycosylation are by far the most common types of PTM found in proteins. The main post-translational modifications associated with proteins are: Acetylation, acylation, ADP-ribosylation, Amidation, γ-Carboxylation and β-hydroxylation, as SUMO has the ability to enhance protein expression and solubility. 38 GPRT is a hydrophobic protein which aggregates and precipates in acidic pH below 6 and is stable at neutral pH whereas CG-T 20 is a hydrophobic peptide (a modified version of Enfuviritide) which aggregates at both neutral and acidic pH. Once the site specific modification is done, aggregation is reduced and solubility is increased at acidic pH with no effect on structure and function. GPRT solubility increases at about 4.8 times the original protein at pH 5 and CG-T 20 peptide solubility increased to 6.2 times at pH 6.
CONJUGATION WITH FATTY ACIDS (LIPIDIZATION)
Irreversible Lipidization Technique -Conventional Lipidization Approach
It improves the lipophilicity of proteins and peptides. Lipidization is a post transcriptional modification of proteins which improves membrane permeability, metabolic stability, bioavailability and changes pharmacokinetic and pharmacodynamic properties of several peptide therapeutics. 2, 39 It involves acylation of the ε-amino group of lysine residues or acylation of N -terminal α -amino groups. 40 The presence of a lipid group in peptides changes their secondary structures, hydrophobicity and self-assembling propensities but retains its ability to bind to target receptors. Cheng et al. produced the analog, Mal-sCT water-soluble (-maleimido lysine derivative of palmitic acid) of salmon calcitonin, a 32-amino acid peptide drug by lipid modification. 41 It was found to have greater stability in-vivo with no compromise in the activity of the peptide. Disadvantages of this technique are that a lipid and a polypeptide are usually incompatible in reaction media, a directly linked lipid-polypeptide conjugate is very likely insoluble in water and lipidized polypeptides in general are of low biological activity.
42,43
Reversible Aqueous Lipidization Technology (REAL):
This is a new method for developing fatty acids-polypeptide conjugates which is carried out in aqueous solution and can regenerate the original active polypeptides in tissues or the blood and thus called REAL Technology. Lipidization has been carried out at cysteine residues following cleavage of intra -disulfide bonds with a reducing agent. This type of lipidization is typically reversible. 42 REAL modified peptides provides increase in git stability, plasma half life and plasma absorption. Reversible lipidization is a simple and effective approach for improving the efficacy of peptide drugs 44 . Shen et al. carried out reversible lipidization of salmon calcitonin, a 32-amino acids polypeptide drug. sCT itself is susceptible towards enzymatic degradation with plasma concentration of 4.6 ± 2.8pg/0.2 mL plasma after 12 hours of oral administration. sCT was reversibly lipidized using a lipidizing agent, N-palmitoylcysteinyl 2-pyridyl disulfide. REAL-sCT formed has modified properties like enhanced oral bioavailability, improved pharmacokinetic and pharmacodynamic behaviour and prolonged release. It has plasma concentration of 7pg/mL plasma after 12 hours of oral administration. REAL-sCT also showed anti-bone resorption activity in ovariectomized (OVX) rats. 42 Wang et al. carried out reversible lipidization of opioid peptide leu-enkephalin (ENK). It has poor oral absorption and is susceptible to enzymatic hydrolysis in small intestine mucosal homogenate (half life-12 min) and liver homogenate (half life-80min).They are devoid of antinociceptive effect when injected intravenously unless suprapharmacological doses (170-320 mg/kg) are used. Lipidizing agent used here was 3,4-bis(decylthiomethyl)-2,5-Furandione (a novel amine-reacting lipophilic dimethylmaleic anhydride analog. REAL product has enhanced stability towards enzymes with 12 fold increment in half life (93 hours).It also has higher an sustained plasma peptide levels upto 24 hours in mice (4.4 times higher) and AUC 21 times higher. It showed a significant and sustained anti-nociception action in rodent inflammatory model. 43 Shen et al. prepared and characterized the reversible lipidizeddipalmitoyldesmopressin and compared its anti-diuretic efficacy and biodistribution with unmodified desmopressin (DDAVP). The intramolecular disulfide bond in DDAVP was reduced using Dithiothreitol (DTT), and the reduced DDAVP was then treated with a lipidization reagent, thiopyridine-containing disulfide, Pal-CPD. Acid precipitation and then size -exclusion was used to purify the product, DPP. The potency of the antidiuretic activity of DDAVP was enhanced to more than 250-fold when DPP when administered to Brattleboro rats subcutaneously. When DDAVP is administered intravenously, the plasma concentration decreased rapidly during the first 20 min followed by slow elimination rate. But in case of DPP administration, the plasma concentration increased in first 20 min followed by slow elimination rate similar to DDAVP injected mice. DDAVP was regenerated and was detected in the plasma of mice treated with DPP. It was found that there was a 250-fold increase in anti-diuretic activity of DDAVP once modified.
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Combination of site specific modification and lipidization technique
Chang et al. used the potential of combining site-specific amino acid substitution and lipid modification to increase the circulating half-lives of ACTH. Cys was used to substitute Phe39 of ACTH which has a free sulfhydryl group. This sulfhydryl group react specifically with iodoacetamide derivatives of lipophilic groups. The biological activities of lipophilized ACTH were higher than native ACTH as it bound more tightly to human serum albumin and cell membranes in vitro and had longer serum half-lives in vivo than native ACTH. These results indicate that the pharmacokinetic properties of peptides can be improved by site-specific substitution with cysteine residues and subsequent conjugation with lipophilic moieties. 45 
HYDROPHOBIC ION PAIRING
Modification of protein by adding an opposite charged surfactant that binds to protein to obtain neutral hydrophobicity entity. Solubility of ionic compounds is high due to ease of solvation of the counter ions with ionic detergents. Positively charged proteins and negatively charged surfactants should be employed, since cationic surfactants might have toxic side effects. 46 Replacement of counter ions decreases the aqueous solubility and increases the lipophilicity. Thus, it changes the partition coefficient by orders of magnitude. HIP method is inexpensive and reversible. The process involves replacement of counter ions (e.g. chloride, acetate, nitrate) with an ionic detergent of similar charge. For many proteins, dissolution in organic solvents occurs with retention of native-like structure and maintenance of enzymatic activity without any chemical modification. 47 Thus, ionpairing is a useful method for increasing the bioavailability of drugs and enhancing permeation of certain drugs.
48 Figure 6 shows the general scheme of hydrophobic ion formation. HIP complex display increases ability to cross biological membrane. Dai et al., Koul et al., Sun et al. prepared insulin hydrophobic ion paired complex using different anionic surfactants like sodium lauryl sulphate, surfoplex, sodium deoxycholate and sodium oleate respectively in 1: 6 ratio (drug : surfactant). [49] [50] [51] [52] The hydrophobic ion paired complex so formed has new properties like increase solubility and partitioning in 1-octanol, retained complex tertiary and secondary structures of insulin. In-vivo activity of insulin is similar to free insulin. Nanoparticles formed using HIP has high entrapment efficiency and higher drug loading as shown by Sun et al and Kendrick et al prepared HIP complex of subtilisin BPN' protein using sodium dodecyl sulphate in 1: 50 ratio (Drug : Surfactant). 51 The new HIP complex of drug so formed maintains native structure of protein, it prevents intermolecular β sheet formation, increased activity as a suspension in iso-octane. 53 Yang et al. prepared HIP complex of water soluble peptide melittin using sodium dodecyl sulphate in 1:6 ratio. The solubility of drug after complexation increases in organic solvent significantly. Its bioactivity is similar to free melittin and entrapment efficiency of drug in PLGA nanoparticles become high. (about 90%). 54 Park et al. prepared HIP complex of leuprolide acetate (an analogue of luteinizing hormone-releasing hormone (LH-RH)) with sodium oleate in 1:1 ratio. Newer features of the complex thus formed is that it becomes more lipophilic. The complex suppresses the immediate burst release of leuprolide from the microspheres in contrast to that prepared from free leuprolide. Both the formulations of microspheres showed constant release profile. 55 Park et al. prepared HIP complex of Salmon calcitonin using sodium oleate as complexing agent. The complexes when incorporated into nanoparticles are readily taken up by Caco2 cells. In-vivo experiments showed that they are readily absorbed orally. 56 Park et al. formed the HIP complex of hen egg white lysozyme which is small protein composed of 129 amino acids residues in 1:6 ratio with SDS or sodium oleate at pH 10.
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COMPLEXATION WITH CYCLODEXTRINS
Proteins and peptides are hindered by unfavourable solubility, aggregation irreversibly or instability. Cyclodextrins are circular oligosaccharides composed of α-(1,4)-linked α-D-glucosyl units. The exterior of cycolodextrin is hydrophilic and its cavity is hydrophobic. This cavity gives it the ability to accommodate hydrophobic molecules/moieties in the cavity. Such an arrangement of molecules provides multiple favorable effects cyclodextrins have on proteins, which is commonly used in pharmacological applications. The most common and industrially utilized cyclodextrins are α-, β-and γ-cyclodextrin, which consist of six, seven and eight glucosyl units. Cyclodextrins are hollow, toroidal, shortened cones. Cones have hydrophilic rims crowned by hydroxyl primary group at 6 th position on the narrow rim and secondary hydroxyl groups on 2 nd and 3 rd position on the wide rim. In contrast, the internal cavity is lined with ether oxygen at 4 th position and hydrogens at 3 rd , 5 th and 6 th position. Various effects of cyclodextrins on different proteins are: protection against degradation (if point of attack of a protease is sterically `masked' by cyclodextrin), aggregation suppression (if residues responsible for aggregation are highly solvent accessible), alteration of function (if residues involved in function are `masked' by cyclodextrin) 7 .
Cyclodextrins' have the ability to use the hydrophobic part present on protein surfaces. This makes them valuable in two areas. Firstly, it helps in the delivery of proteins and small molecules to target site or systemic circulation. For example, hydroxypropyl-β-cyclodextrin enhances the affinity and antagonist potency of a neuromedin B receptor antagonist, the peptide PH 168368, by increasing its solubility while dimethyl-β-cyclodextrin increases the nasal absorption of leucine enkephalin. Secondly, it helps in the stabilization of proteins against aggregation, thermal denaturation and degradation. Thus, cyclodextrins increase the shelf-life of therapeutic proteins, such as growth hormones and insulin. 58 Cyclodextrins have also been suggested to act as `chaperone mimics' by enhancing protein refolding from denatured or even aggregated states. Busrelin acetate, a synthetic nonapeptide, is pyro Glu-His-Trp-SerTyr-D-Ser(tert-butyl)-Leu-Arg-PrO-ethylamide, is a highly potent agonist of lueitnizing hormone-releasing hormone. Drug release from a vehicle is influenced by various factors: Drug-vehicle interactions, solubility, partition coefficient and the particle size of drug in vehicle. Busrelin acetate is practically insoluble in peanut oil and solubility increased slightly on complexation with DE-β-CD ((2,6-di-O-ethyl)-beta-cyclodextrin) or TA-CD's (triacetyl CD). In contrast, the solubility of the CDs in the vehicle increased isin the order of TA-β-CD<TA-γ-CD<DE-β-CD corresponding with the retardation order of buserelin release. Within the oily matrix drug might be dispersed through a weak interaction between CDs and drug. Cyclodextrins play an important role in delivery of oligonucleotides by improving their resistance to nucelases and cellular uptake and by reducing their immunostimulatory properties. 59 The structure of β-CD and formation of inclusion complex is shown in Figure 7 . NOBEX oral drug delivery technology focuses on modification of proteins, peptides and small organic molecules by attaching one or more amphiphilic oligomers. Once these oligomers (water and fat-soluble) are attached, it results in improved solubility to allow optimized formulation, modification of pharmacology to prolong circulating half-life and activity and stability to enzymatic degradation. (Figure 8 ). Creation of amphiphilic oligomers is accomplished by binding a lipophilic alkyl unit to a hydrophilic polyethylene glycol (PEG) unit. The resulting oligomer is then covalently bound to a specific site or sites on the target molecule to facilitate the desired changes in properties of the native drug.The two types of bonds are involved in this technology are hydrolyzable bond at the site of attachment, thus resulting in a pro-drug and non-hydrolyzable bond to create a 'micro-pegylated' drug resulting in inhibition of metabolism of the drug or changes in tissue penetration characteristics, such as facilitation of passage across the blood-brain barriereg. using NOBEX technology, hexyl-insulin-monoconjugate-2 (HIM2) has been developed by covalent attachment of PEG-amphilic oligomer to free amino group on the lysine residue at 20 th position in the β-chain of recombinant human insulin. This modification has enhanced the stability of insulin in presence of gastrointestinal enzymes and facilitate greater absorption. 60 
Emisphere Technology
In Emisphere'seligen TM technology, macromolecules like proteins and peptides are made to interact with small hydrophobic organic compounds non-covalently. This increases their lipophilicity and enhances their absorption. 6 The technology uses of proprietary delivery agents, known as EMISPHERE® delivery agents or carriers with a molecular weight of 250 to 350, and almost all of them are amido acids. The non-covalent interaction transiently alters the physicochemical properties of the macromolecules (e.g., hydrophobicity, conformation, stability, etc.). 61 Several macromolecules have been delivered in humans orally, safely and effectively using this technology . 6 The unique potential of emisphere technology has been tried with macromolecules heparin, insulin, recombinant human growth hormone, salmon calcitonin, and parathyroid hormone leads to significantly higher absorption rates through transcellular route compared to drug alone. They process of carrier-mediated absorption is reversible and thereby ensures that the macromolecule regains its native state and maintains its original therapeutic activity following absorption.
61
CONCLUSION
The peptide and protein based pharmaceuticals thus are rapidly becoming very important class of therapeutic agents. The peptides and proteins based drugs effectively treats various diseases and life-threatening conditions. The improvement in therapies and cure is definite by increasing the alteration in the properties of peptides and proteins. For this various strategies can be used one of which can be structural modification. Modification in the structural moieties of these drugs alters solubility, lipophilicity, stability, crystallinity, targetability, taste and enzymatic susceptibility. For this reason, pharmaceutical and biotechnological companies are doingdifferent researches and testing new techniques for the modifications. By applying these techniques the delivery of such drugs may be possible, as they provide high specificity, bioreactivity, safety, and overall higher success rate.
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